Drugstore.com
This article was originally published in The Tan Sheet
Executive Summary
Online retailer's net sales increase 41% to $84.3 mil. with a net loss of $6.3 mil. in the firm's third quarter, drugstore.com reports Oct. 26. Over-the-counter segment revenues rose 37% to $35.2 mil. due in part to a wider array of nutritional products. CEO Dawn Lepore says the firm has made "encouraging progress in a number of key areas despite a critical management transition and a seasonally challenging period." Lepore took over as CEO in September (1"The Tan Sheet" Sept. 27, 2004, In Brief)...
You may also be interested in...
Drugstore.com leadership
Online retailer appoints Dawn Lepore as CEO, effective Oct. 11. Lepore currently is VP-technology, operations and administration at Charles Schwab, a member of Schwab's executive committee and a trustee of SchwabFunds; she will relinquish all of her Schwab positions when she joins Drugstore.com. Drugstore.com board member Melinda Gates says Lepore "brings a great deal of respect and depth from the e-commerce industry as both a leader and an innovator," having designed Schwab's "entire technology platform" and played a "key role" in that firm's online brokerage business. Lepore replaces interim CEO and current CFO Robert Barton, who took over after Kal Raman stepped down in June (1"The Tan Sheet" June 14, 2004, In Brief)...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.